<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03585777</url>
  </required_header>
  <id_info>
    <org_study_id>VCG 3</org_study_id>
    <nct_id>NCT03585777</nct_id>
  </id_info>
  <brief_title>Compare Serum Klotho Levels in Patients on Oral Antidiabetic Treatment</brief_title>
  <official_title>Serum Klotho Level in Patients on Oral Antidiabetic Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fayoum University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fayoum University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Klotho is a protein found in serum, kidney,heart,brain and in other tissues,it has many
      functions,it is viewed as the anti aging hormone. Aging kidneys are characterized by
      progressive scarring and measurable declines in renal function
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives To study serum klotho level among diabetic patients attending diabetes and
      endocrine clinic in Fayoum university on oral antidiabetic treatment

      Study Design:

      This study will be an observational prospective cohort study. The study duration will be 2
      months.

      Study Methods:

        -  Population of Study

        -  Group 1 :compare serum klotho levels in patients taking glimeperirde versus levels in
           patients taking metformin

        -  Group 2 : compare serum klotho levels in patients taking glimeperirde versus levels in
           patients taking linagliptin

        -  Group 3 : compare serum klotho levels in patients taking glimeperirde versus levels in
           patients taking impaglifluzin

        -  Inclusion Criteria :

        -  Group 1 :Diabetics candidate for oral treatment

        -  Group 2 :Diabetics candidate for oral treatment

        -  Group 3 :Diabetics candidate for oral treatment

        -  Exclusion Criteria :

      Diabetics candidate for insulin treatment

      There will be three arms to this study; the first arm will enroll patients on glimepiride and
      patients on metformin to compare serum klotho levels. The second arm will enroll patients on
      glimepiride and patients on linagliptin to compare serum klotho levels. The third arm will
      enroll patients on glimepiride and patients on impaglifluzin to compare serum klotho levels
      Each arm will enroll 40 patients, 20 patients on glimiperide treatment,20 patient will on the
      other drug,patients will be selected from Fayoum university diabetes and endocrine clinic

      Data collection:

      Patients will be subjected to; full clinical examination,waist hip ratio assessment,BMI
      assessment fasting blood glucose,2PP blood glucose,HbA1C, urea, creatinine, uric acid total
      calcium,albumin, phospherus, estimated GFR, ACR, total cholesterol, triglycerides, serum
      klotho, FGF 23 levels assessment , also fracrtional excretion of phospherus will be assessed.
      Control of blood glucose will be done along the period of the study. At the end of the 2
      months,reassessment of the above mentioned parameters will be done.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">October 11, 2018</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Months</target_duration>
  <primary_outcome>
    <measure>Beneficial effect manifested by a statistical significant decrease in klotho levels</measure>
    <time_frame>2 months</time_frame>
    <description>An anticipated statistical significant decrease in klotho level</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>No beneficial effect manifested by by a non significant decrease in klotho level or a rise in the level</measure>
    <time_frame>2 months</time_frame>
    <description>Non statistical significant decrease in klotho level, or a significant rise in it</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Compare Serum Level of Klotho in Patients on Oral Antidiabetic Treatment</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <description>Compare serum levels of klotho in patients taking glimepiride in comparison to patients taking metformin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <description>Compare serum levels of klotho in patients taking glimepiride in comparison to patients taking linagliptin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <description>Compare serum levels of klotho in patients taking glimepiride in comparison to patients taking impaglifluzin</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        type 2 diabetics on oral treatment
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diabetics candidate for oral treatment

        Exclusion Criteria:

          -  Diabetics candidate for insulin treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ahmed Hammad, MD</last_name>
    <phone>00201001574639</phone>
    <email>aah12@fayoum.edu.eg</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mohammed Mashaheet, MD</last_name>
    <phone>00201227904660</phone>
    <email>mam22@fayoum.edu.eg</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fayoum university Hospital</name>
      <address>
        <city>Fayoum</city>
        <country>Egypt</country>
      </address>
    </facility>
    <contact>
      <last_name>Ahmed Hammad, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>February 9, 2018</study_first_submitted>
  <study_first_submitted_qc>June 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 13, 2018</study_first_posted>
  <last_update_submitted>June 30, 2018</last_update_submitted>
  <last_update_submitted_qc>June 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fayoum University</investigator_affiliation>
    <investigator_full_name>Ahmed Abdelkawi Hammad</investigator_full_name>
    <investigator_title>Lecturer of internal medicine,faculty of medicine,Fayoum university</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

